International audienceCombretastatin A-4 (CSA-4), a stilbene derivative, is a potent vascular disrupting agent (VDA) with the structural requirement of a cis-configuration to maintain a molecular geometry and a correct orientation of both phenyl groups. A series of indolic analogues of CSA-4 was synthesized by means of an efficient strategy. Six compounds (20b, 25b-27b, 32b, and 35b) were identified as potent inhibitors of tubulin polymerization and also displayed cytotoxic activities on B16 melanoma cells at a nanomolar level. Both activities were well correlated with the ability to induce morphological changes of EA.hy 926 endothelial cells. In conclusion, the cis-stilbene skeleton of CSA-4 could conveniently be replaced by the 3-aroylind...
International audienceWe report the synthesis and metabolic and biological evaluation of a series of...
The growing interest in anticancer hybrids in the last few years has resulted in a great number of r...
One promising approach towards cancer treatment involves the use of small-molecule therapeutic agent...
International audienceCombretastatin A-4 (CSA-4), a stilbene derivative, is a potent vascular disrup...
An established strategy in therapeutic oncology entails selectively targeting the tubulin-microtubul...
An array of cis-, trans-, and dihydrostilbenes and some N-arylbenzylamines were synthesized and eval...
Solid tumors depend on a vascular network that delivers nutrients and oxygen, thus selectively targe...
Colchicine site tubulin inhibitors are currently developed as vascular disrupting agents (VDAs). How...
International audienceA series of combretastatin A4 (CA4) analogues with a lactam or lactone ring fu...
Several stilbenoid compounds having structural similarity to the combretastatin group of natural pro...
Vascular-disrupting agents (VDA) specifically target established neovasculature which results in vas...
A promising method for treating cancer involves selectively targeting the tumor vascular network. T...
An investigational approach to cancer treatment involves the use of therapeutic agents that selectiv...
Includes bibliographical references (p. 1-6 [second group]).Over the past years cancer statistics ha...
International audienceThe cytotoxic activity of a series of 23 new isocombretastatin A derivatives w...
International audienceWe report the synthesis and metabolic and biological evaluation of a series of...
The growing interest in anticancer hybrids in the last few years has resulted in a great number of r...
One promising approach towards cancer treatment involves the use of small-molecule therapeutic agent...
International audienceCombretastatin A-4 (CSA-4), a stilbene derivative, is a potent vascular disrup...
An established strategy in therapeutic oncology entails selectively targeting the tubulin-microtubul...
An array of cis-, trans-, and dihydrostilbenes and some N-arylbenzylamines were synthesized and eval...
Solid tumors depend on a vascular network that delivers nutrients and oxygen, thus selectively targe...
Colchicine site tubulin inhibitors are currently developed as vascular disrupting agents (VDAs). How...
International audienceA series of combretastatin A4 (CA4) analogues with a lactam or lactone ring fu...
Several stilbenoid compounds having structural similarity to the combretastatin group of natural pro...
Vascular-disrupting agents (VDA) specifically target established neovasculature which results in vas...
A promising method for treating cancer involves selectively targeting the tumor vascular network. T...
An investigational approach to cancer treatment involves the use of therapeutic agents that selectiv...
Includes bibliographical references (p. 1-6 [second group]).Over the past years cancer statistics ha...
International audienceThe cytotoxic activity of a series of 23 new isocombretastatin A derivatives w...
International audienceWe report the synthesis and metabolic and biological evaluation of a series of...
The growing interest in anticancer hybrids in the last few years has resulted in a great number of r...
One promising approach towards cancer treatment involves the use of small-molecule therapeutic agent...